Opticology - Optical Design & Engineering
Optical Design & Engineering
Optical Fabrication
Opto-Mechanical Design & Fabrication
Product Development
Prototype Fabrication & Manufacture
Software Development
Opticology - Optical Design and Engineering
Optical Crystals
Custom Optical Filters Fabricated From Colored Glass
Research Support
Optical & Opto-Mechanical Assemblies
Opticology - Optical Design & Engineering
Experts in Complex Optical System Design, Development & Implementation
Optical Laboratory & Fabrication Shops
Contact Opticology
Opticology - News & Press
Nanoliter Tear Osmometer
 
Prototype Development and Innovative Optical Engineering Solutions

Opticology, Inc.
135 West 20th St.
3rd Floor
New York, NY 10011
(212) 243-4328

info@opticology.com

<< home

Optical Design & Engineering - News and Press Opticology - Optical Design & Engineering

Opticology to Exhibit at SPIE BiOS 2017,
the largest biophotonics, biomedical optics, and imaging conference.
January 7, 2017

Opticology Inc. will exhibit at SPIE BiOS 2017, a biomedical optics conference preceding SPIE Photonics West. The company intends to showcase its abilities as a contract developer of medical and scientific instruments. Work samples of prototype devices will be on hand as will some of the OEM components it builds for its design clients.

In addition to Opticology's core contract business, the company will also have on display work from its internal development business Opticology Research which is the development arm of the company which has spun off four companies in the medical device and environmental testing fields.

See Opticology, Inc., and Opticology Research including sister companies Tear Glucose Research, Centrofuse Technologies, Lacrisciences, and SPR Technologies at SPIE BiOS, 28 January-2 February 2017, The Moscone Center, San Francisco CA, Space #8454
http://spie.org/conferences-and-exhibitions/photonics-west/bios



Opticology's Affiliate Tear Glucose Research Featured in National Institute for Health Research (UK) Horizon Scanning Review
"New and Emerging Non-Invasive Glucose Monitoring Technologies"
May 16, 2016

Tear Glucose Research (TGR), a spin off company of Opticology, Inc. is named as one of 40 companies identified developing non-invasive glucose monitoring technology to replace finger-stick blood glucose meter currently used by millions who suffer from diabetes. Other companies named in the report include big players Abbott Diabetes Care, Novartis Alcon (Google), and Freedom Meditech.

TGR uses an optical technique, surface plasmon resonance, to measure glucose concentrations in the ocular tears which are known to track blood glucose levels in the body. The device is in the form of a small pen-shaped probe with a small tip sensitized with proprietary glucose sensing chemistry.

Click here for a copy of the report


Opticology Registers for International Traffic in Arms Regulations (ITAR)
October 7, 2015

In an effort to continue its broad appeal to clients in various industries, Opticology, Inc. has completed registration for ITAR through the US Department of State Office of Defense Trade Controls Compliance. ITAR registration is required for companies engaged in manufacturing or exporting defense articles or services pursuant to the Arms Export Control Act. The International Traffic in Arms Regulations (ITAR) website


Opticology Research files patent for field portable detection device
June 12, 2015

The company announced today the filing of an important patent as a result of the work of its research business unit of a field portable system for the detection of chemical and biological agents. Principal Engineer Anthony Cappo comments "We are considered experts in the field of custom surface plasmon resonance (SPR) instruments and in particular miniaturized units. Our clients have expressed a need for a field portable version of the technology that can be used in hostile environments and our latest technology developments fits that bill."

The company intends to commercialize the field-portable sensor platform for a host of detection modalities including heavy metals, residual explosives, or infectious disease that can be measured with precision without the need for laboratory analysis.

Opticology Founder Featured in Crain's New York Business for Work on Tear Glucose
August 5, 2014

Tear Glucose Research, LLC, a biotechnology company spun out of Opticology, Inc. is featured in Crain's New York Business. In the article "Six biotech startups to watch", the company and its founder are featured for the development of a hand held sensing probe to measure the amount of glucose in human tears, a direct correlation to blood glucose.

Team Wins Funding from New York City Economic Development Corporation for Tear Glucose Studies
June 27, 2013

Opticology, Inc. and the New York Eye & Ear Infirmary have been awarded funding for continued development of a diagnostic device for measuring glucose levels in the human tear film. The device has the potential to replace or supplement current finger-prick blood glucose meter used by diabetics, without the pain and inconvenience of drawing blood. Tear glucose can be measured with a gentle touch just above the lower eyelid with a small, portable, pen shaped device.

With the funding, the team will have the opportunity to conduct a clinical study of their handheld device and glucose sensitive chemistry which is attached to the device tip. The award was granted under a New York City Economic Development Corporation initiative PILOT Health Tech NYC.

Opticology Principals to Present at 2013 ARVO Annual Meeting **CLICK HERE TO VIEW POSTER**
February 21, 2013

In partnership with New York Eye & Ear Infirmary and the Lighthouse International, both of New York, Opticology principals Anthony Cappo and Matthew Orr will present their findings from a clinical study entitled A New Method to Depict Central Scotomas: Automated Stereocampimetry at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle this coming May.

Opticology has worked closely with medical researchers in the development of this new device which can measure with precision pathological areas of non-vision on the retina, or scotomas, typically found in patients with age-related macular degeneration or diabetic retinopathy. The device consists of minimal hardware, controlled by software and is installed compactly on modern ophthalmic examination chair swing arm. It is meant to be a low cost alternative yet provide valuable information to the clinician regarding diagnosis and following disease after treatment.

Additional Tear Diagnostic Patent Issues
August 21, 2012

Opticology announced today the issuance of US Patent # 8,249,682 describing a device for measuring concentrations of constituents in tear samples. Long time colleagues Anthony Cappo and Diptabhas Sarkar have spun out a company to commercialize the device for measuring glucose in human tears as an alternative to monitoring blood glucose through finger pricks.

The patent is also being applied toward detection of dye eye syndrome, proteins, viruses, bacteria and other constituents that manifest in the ocular tear film.

Opticology Offshoot Receives Notice of Allowance of Important Patent
May 12, 2012

Opticology announced today that a key US patent for one of its spin-off companies has received a Notice of Allowance from the US patent office. Opticology principal Anthony P. Cappo is primary inventor on the patent which focusses on non-invasive diagnostics via the ocular tear film. Opticology is involved in the development of a new device to measure glucose concentrations in ocular tears as a non-invasive means of determining blood glucose without drawing blood.

The spin-off company, Tear Glucose Research, LLC, has an exclusive license to the patent for glucose determination in tears. The company is developing a novel biosensor and the accompanying handheld device which promises to be a convenient and painless means to measure blood glucose in diabetics.

Opticology Founder Anthony Cappo Featured on Fox Business News
August 2, 2011


In-stock Absorptive Density Filters – UV, VIS, NIR – available for online purchase
March 10, 2011

A long time supplier of custom optical filters, Opticology announced that effective April 1st 2011, it will offer a stock line of absorptive density filters in incremental optical densities designed for the ultraviolet, visible, and near infrared wavelengths. Stock sizes, and density values, and neutral density filter sets, will be offered for purchase via the company website at the
Opticology.com - Online Catalog.

The company plans to introduce stock shortpass, bandpass, and longpass absorptive type filters also available for purchase online in the 4th quarter 2011.

Opticology Spins off Non-Invasive Glucose Co.
April 17, 2010

Principals at Opticology have formed a company to commercialize a new device for measuring glucose concentrations in human tears. The patented technology developed internally at Opticology, is intended as a means to non-invasively measure blood sugar in diabetics. The new company, Tear Glucose Research, LLC, is in cooperation with a university chemistry laboratory and a research hospital. The company is developing a highly sensitive glucose-specific ligand for direct detection of glucose levels in the body via ocular tears.

Principal Engineer Awarded Broad Patent for Human Tear Diagnostics
August 1, 2008

Anthony P. Cappo, Principal Optical Engineer at Opticology, Inc., is the primary inventor on US Patent #7,395,103 which issued July 2008. The patent provides broad protection for a handheld portable probe employing Surface Plasmon Resonance Spectroscopy to directly probe the human tear film. Worldwide patents are pending.

Opticology Principals Ophthalmic Device Patent Issues
December 21, 2007

A key patent in ophthalmic diagnostics issued December 18th. Opticology principals Anthony Cappo and Matthew Orr are key inventors to technology used to measure areas of non-vision in cases of diabetic retinopathy and age-related macular degeneration.

The patent has been assigned to Centrofuse Technologies, LLC.

Tear Diagnostics Moves Towards Commercial Development
April 3, 2007

Opticology announced today that it has assigned its rights and interest to a patent application related to dry eye diagnostics to a new company aptly named LacriSciences, LLC. The new company will focus on commercial development of a direct probing osmometer for detection of dry eye. The company plans to explore using the device for other means of disease detection that manifest in the tear film including bacterial and viral infections.

The company was formed in partnership with world renowned expert on dry eye and the ocular tear film Jeffrey P. Gilbard, MD. Dr. Gilbard was the first to develop tear osmolarity as a diagnostic test in 1976, and is the Founder, CEO and Chief Scientific Officer of Advanced Vision Research, makers of TheraTears. Opticology will continue to participate in the early stage design and development of the device.

Older News

NIH Funds Dry Eye Diagnostic Device
September 30, 2004

Opticology, Inc. (New York, NY) has been granted a Phase I STTR award for the continued development of a Nanoliter Tear Osmometer in cooperation with the Aborn Eye Research Center (New York, NY).
The award was made by the National Institutes of Health’s National Eye Institute.

Tear osmolarity, well accepted as the objective measure for presence and degree of Dry Eye Syndrome, is not widely used in clinical practice due to the lack of a commercially available osmometer that can measure nanoliter sample volumes.

is believed to be a disruption in the stability of the tear film Dry Eye Syndrome caused by a deficiency of one of the three components that make up a tear. Dry Eye affects a large percentage of the population with symptoms predominately of discomfort, yet can cause progressive pathological changes in the conjunctiva and corneal epithelium.

Despite it prevalence, Dry Eye has been difficult to accurately diagnose, as the Dry Eye symptoms can be misinterpreted as evidence of other conditions. The recent introduction of prescription pharmaceuticals for Dry Eye treatment has accentuated the lack of instrumentation engineered specifically for Dry Eye detection, and thereby heightened the timeliness of Opticology’s research.

Opticology, Inc. Expands Product Development Group
August 10, 2004

Opticology announced today the expansion of its Product Development Group to further broaden and solidify the company’s role in prototype development and innovative optical engineering solutions.  The enhancements will streamline prototyping services for the medical device industry, corporate and academic level R&D, and core business customers.

Improvements include a 4-axis computer controlled machining center, the addition of state-of-the-art CAD and CAM software, and several improvements to the physical workspace.  Furthermore, the onsite staff has been expanded to include an Industrial Designer.

“Our customers expect their jobs to be done quickly, and done right” explains Tony Cappo, Principal Engineer at Opticology.  “The expanded capability allows us to get more of the job done in-house, avoiding the pitfalls with outside labor.  Both our clients and our internal projects will experience more innovative designs, even more attention to detail, and a faster development cycle.” 

The growth continues Opticology’s history of designing and building custom optical and opto-mechanical systems.  In response to the increased use of optics in medical devices and the like, full services are offered in proof-of-concept, prototype, and production-ready systems.

NIH Awards Phase II STTR Grant to Opticology, Inc. and Aborn Eye Research Laboratory
July 1, 2003

Opticology, Inc. (New York, NY) has been awarded a Phase II Small Business Technology Transfer grant in collaboration with the Aborn Eye Research Laboratory (New York, NY) from the National Institutes of Health’s National Eye Institute. The two will continue research funded in Phase I, toward the development of a visual field device specifically designed to accurately depict centrally located pathological areas of non-vision on the retina.

The alliance has developed a prototype ophthalmic instrument which addresses the shortcomings of commercially available perimeters, which fail to produce accurate results in patients with centrally located retinal defects such as age-related macular degeneration and diabetic retinopathy due to their inability to fixate. The instrument uses a combination of sophisticated software and optical hardware and has been clinically shown to enable patients to maintain fixation during an exam, allowing measurements of the central and paracentral visual field with unprecedented accuracy.

The intention of the Phase II research is to design the instrument for commercialization and incorporate all the features of a modern perimeter, with the ability to render an accurate depiction of central retinal defects previously unattainable in an office setting. Clinical trials will continue at the New York Eye & Ear Infirmary (New York, NY).

Opticology Introduces Beta Version of Full-Color LED Based Fiber Optic Illuminator
January 31, 2003

Opticology, Inc. has released preliminary product that has applications in machine vision and general color-sensitive systems requiring optical illumination. The unit launches light from multiple ultra-bright LED’s into a diameter fiber bundle. Light output is adjustable in intensity, but also color – either pure red, green, or blue OR any mix of the three allowing the user to obtain virtually any color output. Even varying shades of white can be produced yellow-white, blue-white, etc. mimicking varying color temperatures.

Ideal for machine vision applications where illumination of objects in a particular color band can boost signals. Also beneficial for transilluminated and reflected microscopy where colored illumination is beneficial and heat can cause problems.

The device benefits from advantages of LED’s – low power consumption, long lifetimes, and minimal heat generation. There are no bulbs to replace, no bulk transformers, no fans, and the output light does not vary with time. No color filters, no heat filters, on-the-fly color adjustment, and high output. Opticology is offering custom versions of the device at this time, competitively priced with conventional units.

For pictures and more information on the device please go to our Standard Products page.

NIH Awards Grant to Ophthalmic Research Laboratory and Optical Engineering Firm
October 24,
2001
 
A Phase I Small Business Technology Transfer grant has been awarded to Opticology, Inc. (New York, NY) in conjunction with the Aborn Eye Research Center (New York, NY), for the continued development of an ophthalmic device to accurately measure centrally located pathological areas of non-vision on the retina. The award has been made by the National Institutes of Health’s National Eye Institute.

The alliance has demonstrated new technology that enables a patient that suffers from diseases such as macular degeneration and other centrally located retinal defects to maintain fixation, enabling measurements of their central and paracentral visual field with unprecedented accuracy. It is intended to make the device available clinically, and uses a combination of sophisticated software and optical hardware to perform the measurements. Clinical trials of the prototype device will be performed at the New York Eye and Ear Infirmary (New York, NY).


Opticology, Inc., Old Chelsea Station, P.O. Box 1080, New York, NY 10113. Tel: 212-243-4328; Fax: 212-366-5508.


back to home page